Mechanism and clinical significance of prostaglandin-induced iris pigmentation

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Stjernschantz, Johan W ^a   Albert, Daniel M ^b   Hu, Dan Ning ^c   Drago, Filippo ^d   Wistrand, Per J ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Bimatoprost; Eye color; Glaucoma; Heterochromia; Iridial melanocytes; Isopropyl unoprostone; Latanoprost; Melanogenesis; Prostaglandin induced iris pigmentation; Travoprost

Indexed keywords

BIMATOPROST; LATANOPROST; MELANIN; MONOPHENOL MONOOXYGENASE; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

AQUEOUS HUMOR FLOW; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; EYE COLOR; GLAUCOMA; HUMAN; HYPERPIGMENTATION; IMMUNOHISTOCHEMISTRY; MELANOGENESIS; MELANOMA CELL; NONHUMAN; PIGMENT CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REVIEW;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DINOPROST; EYE COLOR; GENE EXPRESSION REGULATION; HUMANS; IRIS; IRIS DISEASES; LIPIDS; MELANOCYTES; MONOPHENOL MONOOXYGENASE; PIGMENTATION DISORDERS; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; UP-REGULATION;

EID: 0036669681     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00292-8     Document Type: Review

References (100)

1. Abdel-Malek Z.A. Endocrine factors as effectors of integumental pigmentation. Dermatol Clin. 6:1988;175-183.
2. 2 determined by using a 5-bromo-2′-deoxyuridine method of DNA analysis. J Cell Physiol. 136:1988;247-256.
3. Albert D.M., Green W.R., Grossniklaus H.E.et al. Histopathological findings in iris specimens from patients with glaucoma treated with latanoprost. Invest Ophthalmol Vis Sci. 41(Suppl):2000;2712. [abstract].
4. Alm A., Stjernschantz J. The Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol Ophthalmology. 102:1995;1743-1752.
5. Araki K., Horikawa T., Chakraborty A.K.et al. Small HGTPase rab3A is associated with melanosomes in melanoma cells. Pigment Cell Res. 13:2000;332-336.
6. 2 receptors. Proc Natl Acad Sci USA. 95:1998;15792-15797.
7. Bito L.Z., Matheny A., Cruickshankset al. Eye color changes past early childhood. The Louisville Twin study. Arch Ophthalmol. 155:1997;659-663.
8. 2. Invest Ophthalmol Vis Sci. 24:1983;376-380.
9. Brown S.M. Increased iris pigment in a child due to latanoprost. Arch Ophthalmol. 116:1998;1683-1684.
10. Burkhardt A. Zur Farbe und Struktur der menschlichen Iris. 1. Morphologische Untersuchungen. Antropol Anz. 50:1992;83-126.
11. Byrne P., Clough C. Hypochromia iridis in aquired Horner's syndrome. J Neurol Neurosurg Psychiatry. 55:1992;415.
12. Böshaar E: Altersveränderungen der Augenfarbe. Homo 5:164-9, 1954
13. Calhoun F.P. Causes of heterochromia iridis with special reference to paralysis of the cervical sympathetic. Am J Ophthalmol. 2:1919;255-268.
14. Camras C.B., Neely D.G., Weiss E.L. Latanoprost-induced iris color darkening. a case report with long-term follow-up J Glaucoma. 9:2000;95-98.
15. Camras C.B. The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States Ophthalmology. 103:1996;138-147.
16. Camras C.B., Zhan G.-L., Wang Y.-L., Toris C.B. Experimental model for prostaglandin (PG)-induced iris color darkening (ICD) - effect of isopropyl unoprostone (UP). Invest Ophthalmol Vis Sci. 41(Suppl):2000;3999. [abstract].
17. Cantor L.B. AGN 192024 Study Group 1&2. 6-month comparison of AGN 192024 once daily and twice daily with timolol twice daily in patients with elevated IOP Invest Ophthalmol Vis Sci. 42(Suppl):2001;2998. [abstract].
18. Chau R., Su P., Niggeman B.et al. Evaluation of iris color changes in cynomolgus monkeys following administration of unoprostone isopropyl. Invest Ophthalmol Vis Sci. 40(Suppl):1999;3568. [abstract].
19. Coleman R.A., Kennedy I., Humphrey P.P.A.et al. Prostanoids and their receptors. Emmett J.C. Comprehensive Medicinal Chemistry, Vol 3, Membranes and Receptors. 1990;643-714 Pergamon Press, Oxford.
20. Coleman R.A., Smith W.L., Narumiya S. VIII International union of pharmacology classification of prostanoid receptors. properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev. 46:1994;205-229.
21. Diesenhouse M.C., Palay D.A., Newman N.Y.et al. Aquired heterochromia with Horner's syndrome in two adults. Ophthalmology. 99:1992;1815-1817.
22. Drago F., Marino A., La Manna C. α-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res. 68:1999;85-90.
23. Dryja T.P., Albert D.M. Lack of adrenergic influence on the pigmentation of iris nevus cells. Arch Ophthalmol. 98:1980;1996.
24. Dutkiewicz R., Albert D.M., Levin L.A. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 70:2000;563-569.
25. Eagle R.C. Jr. Iris pigmentation and pigmented lesions. an ultra-structural study Trans Am Ophthalmol Soc. 86:1988;581-687.
26. Ehinger B. Adrenergic nerves to the eye and to related structures in man and in the cynomolgus monkey (Macaca irus). Invest Ophthalmol. 5:1966;42-52.
27. Ehinger B., Falck B. Innervation of iridic melanophores. Z Zellforsch. 105:1970;538-542.
28. Freddo T.F. Ultrastructure of the iris. Microsc Res Tech. 33:1996;369-389.
29. Friedmann P.S., Wren F.E., Matthews J.N.S. Ultraviolet stimulated melanogenesis by human melanocytes is augmented by D-acyl glycerol but not TPA. J Cell Physiol. 142:1990;334-341.
30. Friström B., Nilsson S.E.G. A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. Br J Ophthalmol. 81:1997;867-870.
31. Gordon P.R., Mansur C.P., Gilchrest B.A. Regulation of human melanocyte growth, dendricity, and melanization by keratinocyte derived factors. J Invest Dermatol. 92:1989;565-572.
32. Grierson I., Lee W.R., Albert D.M. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol. 117:1999;394-396.
33. Grierson I., Pfeiffer N. The morphology of irides treated with latanoprost. Diestelhorst M. Prostaglandins in Ophthalmology. 1998;105-110 Kaden, Heidelberg.
34. Grierson I., Cracknell K.P.B., Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol. 12:2001;112-118.
35. Gudermann T., Grosse R., Schultz G. Contribution of receptor/G protein signaling to cell growth and transformation. Naunyn-Schmiedeberg's Arch Pharmacol. 361:2000;345-362.
36. Hearing V.J. The melanosome. the perfect model for cellular responses to the environment Pigment Cell Res. 13(Suppl 8):2000;23-34.
37. Hesch M. Über Pigmentierungsverhältnisse der menschlichen Iris nach Alter und Gesclecht. Beziehungen zwichen Augenfarbe, Struktur und Ringbildung. Verh Ges Phys Antropol. 5:1931;9-25.
38. Higginbotham E.J. AGN 192024 Study Group 1. 1-year comparison of the new prostamide AGN 192024 with timolol for the management of glaucoma and ocular hypertension Invest Ophthalmol Vis Sci. 42(Suppl):2001;3002. [abstract].
39. Hiller R., Sperduto R.D., Kreuger D.A. Race, iris pigmentation and intraocular pressure. Am J Epidemiol. 115:1982;674-683.
40. Hu D.-N., McCormick S.A., Orlow S.J.et al. Melanogenesis by human uveal melanocytes in vitro. Invest Ophthalmol Vis Sci. 36:1995;931-938.
41. Hu D.-N., McCormick S.A., Lin A.Y., Lin J.Y. TGF-β2 inhibits growth of uveal melanocytes at physiological concentrations. Exp Eye Res. 67:1998;143-150.
42. 2α and latanoprost on cultured human iridial melanocytes. Exp Eye Res. 70:2000;113-120.
43. Hu D.-N., Woodward D.F., McCormick S.A. Influence of autonomic neurotransmitters on human uveal melanocytes in vitro. Exp Eye Res. 71:2000;217-224.
44. Hu F. Aging of melanocytes. J Invest Dermatol. 73:1979;70-79.
45. Hu F., Mah K. Changes in melanosomes with age in iridial stromal melanocytes of rhesus macaques. Mech Ageing Dev. 23:1983;95-102.
46. Imesch P.D., Bindley C.D., Khademian Z.et al. Melanocytes and iris color. Arch Ophthalmol. 114:1996;443-447.
47. Imesch P.D., Wallow I.H.L., Albert D.M. The color of the human eye. a review of morphologic correlates and of some conditions that affect iridial pigmentation Surv Ophthalmol. 41(Suppl 2):1997;S117-S123.
48. Iwaguchi Y., Tanahashi T., Shirato H. Two cases of iris color change after instillation of isopropyl unoprostone. Rinsho Ganka. 53:1999;971-974.
49. Jones N.P. Fuch's heterochromic uveitis. an update Surv Ophthalmol. 37:1993;253-272.
50. Koganei J. Untersuchungen über den Bau der Iris des Menschen under der Wirbeltiere. Arch Mikr Anat. 25:1885;1.
51. Lake S., Krook K., Lundgren M.et al. Effect of latanoprost on the transcription of tyrosinase and TRP1 in cultivated human iridial melanocytes. Invest Ophthalmol Vis Sci. 38(Suppl):1997;3793. [abstract].
52. Laties A.M. Ocular melanin and the adrenergic innervation to the eye. Trans Am Ophthalmol Soc. 72:1974;560-605.
53. Laties A.M., Lerner A.B. Iris colour and relationship of tyrosinase activity to adrenergic innervation. Nature. 255:1975;152-153.
54. Lenart T.D., Drack A.V., Tarnuzzer R.W.et al. Heterochromia after pediatric cataract surgery. J AAPOS. 4:2000;40-45.
55. Lindquist N.G., Larsson B.S., Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res. 68:1999;431-436.
56. 3H-methimazole, a specific marker of melanin synthesis. Exp Eye Res. 67:1998;259-264.
57. Lindsey J.D., Jones H.L., Hewitt E.G.et al. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch Ophthalmol. 119:2001;853-860.
58. Lopez-Ilasaca M., Crespo P., Pellici P.G.et al. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ Science. 275:1997;394-397.
59. Mayou MS: Heterochromia iridis associated with paralysis of the sympathetic in early life. Ophthalmic Review XXIX:190, 1910
60. Meyer-König L. Altersveränderungen den Augen- und Haarfarbe, eine Längsschnittuntersuchung. Antropol Anz. 35:1975;24-41.
61. Mikko S, Bergh K, Stjernschantz J: Effect of Latanoprost Acid on Transcription of Melanogenic Genes in Cultivated Human Iridial Melanocytes
62. Moses R.A. The iris and the pupil. Moses R.A. Adler's Physiology of the Eye. 1970;372-404 CV Mosby, St Louis.
63. Mukuno K., Witmer R. Innervation of melanocytes in human iris. An electron microscopic study. Graefes Arch Clin Exp Opthalmol. 203:1977;1-8.
64. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors. structures, properties, and functions Physiol Rev. 79:1999;1193-1226.
65. Netland P.A., Landry T., Silver L.H.et al. IOP-lowering efficacy and safety of travoprost compared to latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 42(Suppl):2001;2984. [abstract].
66. 2 but not MSH stimulate the proliferation of pigment cells in the pinnal epidermis of the DBA/2 mouse. J Invest Dermatol. 86:1986;433-437.
67. Norris D.A., Morelli J.G., Fujita M. Melanocyte interactions in the skin. Nordlund J.J., Boissy R.E., Hearing V.J.et al. The Pigmentary System. Physiology and Pathophysiology. 1998;123-133 Oxford University Press, New York.
68. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci. 37:1996;716-726.
69. Oda E., Matsumoto S., Washimi I. Iridial pigmentation possibly caused by isopropyl unoprostone. Ganka. 41:1999;1479-1483.
70. Odin L., O'Donnell F.E. Jr. Adrenergic influence on iris stromal pigmentation. evidence for alpha-adrenergic receptors Invest Ophthalmol Vis Sci. 23:1982;528-530.
71. Orlow S.J. The biogenesis of melanosomes. Nordlund J.J., Boissy R.E., Hearing V.J.et al. The Pigmentary System. Physiology and Pathophysiology. 1998;97-106 Oxford University Press, New York.
72. Pappas R.M., Pusin S., Higginbotham E.J. Evidence of early change in iris color with latanoprost use. Arch Ophthalmol. 116:1998;1115-1116.
73. Park H.-Y., Gilchrest B.A. Protein kinase C. biochemical characteristics and role in melanocyte biology J Dermatol Sci. 6:1993;185-193.
74. Park H.-Y., Perez J.M., Laursen R.et al. Protein kinase C-β activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain. J Biol Chem. 274:1999;16470-16478.
75. Pfeiffer N., Grierson I., Sell E.et al. Morphological evaluation of the iris after treatment with latanoprost. Invest Ophthalmol Vis Sci. 38(Suppl):1997;1134. [abstract].
76. Prota G., Hu D.-N., Vincensi M.R.et al. Characterization of melanins in human irides and cultured uveal melanocytes from eyes of different colors. Exp Eye Res. 67:1998;293-299.
77. Prota G., Vincensi M.R., Napolitano A.et al. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 13:2000;147-150.
78. Ringvold A. An electron microscopic study of the iris stroma in monkey and rabbit with particular reference to intercellular contacts and sympathetic innervation of anterior layer cells. Exp Eye Res. 20:1975;349-365.
79. Schraermeyer U. Evidence for melanogenesis in the retinal pigment epithelium of adult cattle and golden hamster. Comp Biochem Physiol. 103B:1992;435-442.
80. Schraermeyer U. Does melanin turnover occur in the eyes of adult vertebrates? Pigment Cell Res. 6:1993;193-204.
81. Scott G., Zhao Q. Rab3a and SNARE proteins. potential regulators of melanosome movement J Inv Dermatol. 116:2001;296-304.
82. Selén G., Stjernschantz J., Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol. 41(Suppl 2):1997;S125-S128.
83. Stjernschantz J. Significance and time-course of prostaglandin-induced increase in iridial pigmentation in primates and man. Diestelhorst M. Prostaglandins in Ophthalmology. 1998;111-116 Kaden, Heidelberg.
84. Stjernschantz J., Ocklind A., Wentzel P.et al. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol Scand. 78:2000;618-622.
85. 2α-isopropyl ester to latanoprost. A review of the development of Xalatan. The Proctor lecture. Invest Ophthalmol Vis Sci. 42:2001;1134-1145.
86. Sugita A., Tanaka T., Yoshioka H. Age-related changes of iris stromal melanocytes in human eyes. Jpn J Ophthalmol. 30:1986;174-179.
87. Suzuki M., Mishima H.K., Masuda K.et al. Efficacy and safety of latanoprost eye drops for glaucoma treatment. a 1-year study in Japan Jpn J Ophthalmol. 44:2000;33-38.
88. Takai Y., Sasaki T., Matozaki T. Small GTP-binding proteins. Physiol Rev. 81:2001;153-208.
89. Taylor A.J. Eye colour in the Tristan Da Cunha population. Human Biol. 39:1967;316-318.
90. Tomita Y., Maeda K., Tagami H. Melanocyte-stimulating properties of arachidonic acid and metabolites. possible role in postinflammatory pigmentation Pigment Cell Res. 5:1992;357-361.
91. Watson P., Stjernschantz J. The Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension Ophthalmology. 103:1996;126-137.
92. Wentzel P, Bergh K, Wallin Ö et al.: Transcription of Prostanoid Receptor and Cyclo-oxygenase Enzyme Genes in Cultivated Human Iridial Melanocytes from Eyes of Different Color. (in preparation).
93. Wilkerson C.L., Syed N.A., Fisher M.R.et al. Melanocytes and iris color. Arch Ophthalmol. 114:1996;437-442.
94. Winder A., Kobayashi T., Tsukamoto K.et al. The tyrosinase gene family-interactions of melanogenic proteins to regulate melanogenesis. Cellular and Molecular Biology Research. 40:1995;613-626.
95. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 41(Suppl 2):1997;S129-S138.
96. Wobmann P.R., Fine B.S. The clump cells of Koganei. A light and electron microscopic study. Am J Ophthalmol. 73:1972;90-101.
97. Wolfrum P. Über den Bau der Irisvorderfläche des menschliche Auges mit vergleichend anatomischen Bemerkungen. Graefes Arch Clin Exp Ophthalmol. 183:1922;317-333.
98. Yamamoto T., Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma. 6:1997;430-432.
99. Zhan G.-L., Toris C.B., Camras C.B.et al. Prostaglandin-induced iris color darkening. An experimental model. Arch Ophthalmol. 116:1998;1065-1068.
100. Zinn K.M., Mockel-Pohl S., Villanueva V., Furman M. The fine structure of iris melanosomes in man. Am J Ophthalmol. 76:1973;721-729.